Mayer Brown and the Center for Health & Pharmaceutical Law & Policy, Seton Hall University School of Law presented on March 2, 2017 a symposium exploring emerging issues and legal trends impacting the life sciences industry, including:
- What’s Next for the FDA Under the New Administration and How Companies Can Prepare
- The Future of Biosimilars: Regulatory, Legislative and Case Law Developments Impacting the Industry
- Advertising by the Pharmaceutical Industry on Social Media: Pitfalls to Avoid
- Navigating Conflicts and Ethical Considerations in Mergers & Acquisitions
- Criminal Enforcement Trends in the Life Sciences Industry
The Honorable Michael Chagares, the United States Court of Appeals for the Third Circuit, gave a special keynote address. The program offered the opportunity for participants to network with in-house counsel, academics, members of the judiciary, and industry representatives. Additional speakers included:
Additional speakers included:
- Gaia Bernstein, Michael J. Zimmer Professor of Law, Director, Seton Hall Institute for Privacy Protection, Co-Director, Gibbons Institute of Law Science and Technology, Seton Hall University School of Law
- Tom DiLenge, President, Advocacy, Law & Public Policy Division, BIO
- Howard Dorfman, Distinguished Practitioner in Residence, Visiting Professor, Seton Hall University School of Law
- Edward Hartnett, Richard J. Hughes Professor of Law, Seton Hall University School of Law
- Stephen Lubben, Harvey Washington Wiley Chair, Corporate Governance & Business Ethics, Seton Hall University School of Law
- Jeff Myers, Vice President & Assistant General Counsel, Pfizer
- Mark Rachlin, Senior Patent Counsel-Litigation, GlaxoSmithKline
- Brian Walsh, Assistant General Counsel – IP, Bristol-Myers Squibb Company
- Denelle Waynick, Vice President, Legal Affairs, UCB
- Byron Webster, Director, Leerink Partners
Event Materials
The Future of FDA and Biosimilars
Mergers & Acquisitions: Ethical Considerations
Excerpts: Model Rules of Ethical Conduct
Media Coverage
Biosimilar Rules Likely To Survive ACA Battle, Lawyers Say
5 Social Media Pitfalls In The Pharmaceutical Industry
What Current Legal Developments Mean For Biosimilars
What Companies Can Expect From The New FDA
For a write-up of this event please visit Seton Hall's website.
Please visit law.shu.edu.